Neumora Therapeutics Reports Q4 and Full Year 2025 Financial Results: Major Pipeline Progress and Key Catalysts Ahead

Summary

Neumora Therapeutics, Inc. (Nasdaq: NMRA) has released its financial and operational results for the fourth quarter and full year ended December 31, 2025. The company, focused on novel treatments for brain diseases, delivered several significant updates across its advanced clinical pipeline, highlighted new data releases, and provided updated guidance on cash runway and upcoming milestones. These developments could have substantial implications for shareholders and the company’s share price.

Key Highlights and Potential Price Sensitive Events

1. NMRA-511: Promising New Data in Alzheimer’s Disease Agitation

• New Phase 1b Data: Neumora released new data from a pre-specified analysis of its ongoing Phase 1b study in Alzheimer’s disease (AD) agitation. In patients with a Neuropsychiatric Inventory Agitation/Aggression (NPI-AA) score ≥4—criteria aligned with pivotal studies for other drugs—NMRA-511 demonstrated a Cohen’s d effect size of 0.34 on the CMAI total score and 0.51 on the CMAI aggression sub-factor score at Week 8.
• Across other endpoints (including Clinical Global Impression-Severity and NPI-AA), NMRA-511 showed unsurpassed effect sizes and maintained a favorable tolerability and safety profile.
• Upcoming Milestones: Multiple ascending dose (MAD) cohort data for higher doses of NMRA-511 are expected in 2H 2026, and a Phase 2 study in AD agitation is set to initiate in Q1 2027.
• Shareholder Impact: Positive data and advancement into later-phase studies could drive significant investor interest and valuation re-rating.

2. Navacaprant: Key Study Readouts Approaching

• The KOASTAL-2 and KOASTAL-3 studies, each with over 400 patients enrolled, were fully enrolled in Q1 2026. A joint topline data readout is expected in Q2 2026, including pre-specified analyses with over 450 patients following study optimizations.
• Shareholder Impact: Upcoming data readouts from these pivotal studies are likely to be significant share price catalysts, as positive efficacy/safety outcomes could accelerate commercialization prospects or partnerships.

3. NMRA-898 (M4 PAM Franchise): Advancement in Schizophrenia

• NMRA-898 has been selected as the lead program in Neumora’s M4 positive allosteric modulator (PAM) franchise, based on promising Phase 1 clinical data.
• Key findings include: 80-100 hour half-life (potential for once-daily dosing), dose-proportional exposures, brain free exposures above in vitro M4 EC50, exposure-dependent increases in heart rate (pharmacodynamic evidence of target engagement), and a favorable safety profile to date.
• A MAD study is ongoing in healthy volunteers and patients with stable schizophrenia. Results from this study are expected in 2H 2026.
• Shareholder Impact: The selection of NMRA-898 for further development, and its potential differentiation from competitors, could attract investor attention and strategic interest from partners.

4. NMRA-215: Progress and Unexpected Toxicology Findings

• In a 12-week diet-induced obesity (DIO) mouse study, NMRA-215 demonstrated sustained, semaglutide-like weight loss after switching from semaglutide monotherapy or combination therapy, supporting its potential for switch and maintenance settings in obesity.
• 28-day rat and dog and 13-week dog toxicology studies showed high safety margins. However, a 13-week rat toxicology study revealed unexpected adverse findings in 5 of 142 animals. These were not dose-dependent and were not linked to known drug or target effects. Neumora believes these may be due to study conduct issues and has initiated a for-cause audit while repeating the study at a different CRO.
• Clinical studies for NMRA-215 in obesity are now expected to start in Q1 2027, with further guidance on data readouts to come.
• Shareholder Impact: The unexpected toxicology findings introduce an element of risk and could weigh on sentiment until further clarity is provided. However, rapid resolution and positive repeat study results could reverse this.

5. Financial Position and Guidance

• Cash and Equivalents: \$182.5 million as of December 31, 2025, expected to fund operations into Q3 2027.
• R&D Expenses: \$44.7 million in Q4 2025 (vs. \$45.9 million in Q4 2024); \$176.1 million for FY 2025 (down from \$200.9 million in 2024) due to lower navacaprant and personnel costs.
• Net Loss: \$59.4 million in Q4 2025 (vs. \$58.8 million in Q4 2024); \$236.9 million for FY 2025 (vs. \$243.8 million in 2024).
• Total Liabilities: \$87.2 million; Total Stockholders’ Equity: \$103.9 million as of year-end 2025.
• Shareholder Impact: Solid financial runway reduces near-term dilution risk but ongoing R&D spending and clinical timelines will continue to be closely monitored by investors.

Other Notable Items

• Neumora’s press release includes cautionary language regarding forward-looking statements, drug development risks, and the interpretation of comparative efficacy data.
• The company’s mission remains focused on redefining neuroscience drug development and addressing significant unmet needs in brain diseases.

Conclusion

Neumora Therapeutics is entering a catalyst-rich period in 2026 and 2027, with major clinical data readouts and regulatory milestones ahead for its lead programs. Key value drivers include the NMRA-511 Alzheimer’s agitation program, navacaprant pivotal trial readouts, and advancement of NMRA-898 and NMRA-215. Investors should monitor updates on toxicology study outcomes for NMRA-215, as well as the timing and results of upcoming clinical trials, which could significantly influence the company’s valuation and share price. The company’s strong financial position provides a buffer to reach these milestones without imminent capital raises.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All statements regarding future events are subject to risks and uncertainties as described in Neumora Therapeutics’ SEC filings. Investors should conduct their own due diligence and consult a qualified financial advisor before making investment decisions.

View Neumora Therapeutics, Inc. Historical chart here